- Company to provide update on Type B meeting with FDA on Phase 3 clinical trial design for FCX-007 gene therapy candidate for recessive dystrophic epidermolysis bullosa (RDEB) -
- Company to highlight updated data from ongoing FCX-007 Phase 1/2 clinical trial for RDEB -
EXTON, Pa., March 20, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced it will report financial results for the year ended December 31, 2018 and operational highlights on March 27, 2019 before the open of the U.S. financial markets.
John Maslowski, President and Chief Executive Officer of Fibrocell, will host a conference call and webcast at 8:30 a.m. EDT on the same day to discuss the Company’s financial results. In addition, he will discuss the recent Type B end-of-Phase 2 meeting with the U.S. Food and Drug Administration regarding the Phase 3 clinical trial design for FCX-007, Fibrocell’s gene therapy candidate for the treatment of RDEB. Furthermore, Mr. Maslowski will provide additional data and address progress from the ongoing Phase 1/2 clinical trial of FCX-007 for the treatment of RDEB.
A corporate slide presentation will be referenced during the call and will be posted in the Investors section of the Company’s website www.fibrocell.com/investors/events under the event, “2018 Financial Results & Recent Highlights.” Following the presentation, there will be a question-and-answer session with Mr. Maslowski and Alfred Lane, MD, Chief Medical Advisor of Fibrocell and Professor of Dermatology and Pediatrics (Emeritus) at the Stanford University School of Medicine.
Fibrocell Conference Call & Webcast
To participate on the live call, please dial 888-394-8218 (domestic) or +1-323-794-2588 (international), and provide the conference code 8315981 five to ten minutes before the start of the call. The conference call will also be webcast live under the investor relations section of Fibrocell's website at www.fibrocell.com/investors/events and will be archived there for 30 days following the call.
Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of RDEB. Fibrocell is also developing FCX-013, the Company’s clinical stage candidate for the treatment of moderate to severe localized scleroderma. Fibrocell’s gene therapy portfolio is being developed in collaboration with Intrexon Corporation (XON), a leader in synthetic biology. For more information, visit www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.
Fibrocell®, the Fibrocell logo, and Fibrocell Science® are trademarks of Fibrocell Science, Inc. and/or its affiliates. All other names may be trademarks of their respective owners.
Investor & Media Relations Contact: